Skip to content
Open access

Integrated pathway analysis of small cell lung cancer: NOTCH alterations as an independent favorable prognostic factor and DNA damage repair alterations as correlates of tumor mutational burden

2026 · The Atlantic Journal of Medical Science and Research · 0 citations

TL;DR

NotCH alterations serve as an independent favorable prognostic marker, while DDR alterations associate with elevated TMB without independent prognostic impact, and these findings validate NOTCH as a prognostic biomarker in SCLC and support pathway-level genomic assessment in clinical risk stratification.

Abstract

Aim: Small cell lung cancer (SCLC) is characterized by near-universal TP53/RB1 inactivation and high mutation burden, yet prognostic biomarkers beyond clinical stage remain limited. This study aimed to characterize pathway-level genomic alterations—including DNA damage repair (DDR), NOTCH, mismatch repair (MMR), and MYC family—and evaluate their associations with tumor mutational burden (TMB) and overall survival in a whole-genome sequenced SCLC cohort. Materials and Methods: We analyzed genomic and clinical data from 120 primary SCLC tumors in the University of Cologne cohort, accessed via cBioPortal. A 34-gene panel spanning homologous recombination, DNA damage signaling, Fanconi anemia, MMR, NOTCH (NOTCH1/2), cell cycle regulators (TP53, RB1), and MYC family genes was interrogated. Pathway co-occurrence was assessed using Fisher\'s exact tests. TMB comparisons used Mann-Whitney U tests. Overall survival was analyzed via Kaplan-Meier estimates, log-rank tests, and multivariable Cox proportional hazards regression adjusted for age, sex, tumor stage, and chemotherapy. Results: TP53 (85.8%) and RB1 (72.5%) alterations co-occurred strongly (odds ratio [OR] = 20.6, p < .001). DDR pathway alterations were present in 26.7% of tumors, with homologous recombination-altered cases showing markedly elevated TMB (median 12.6 vs 7.0, p = .001). NOTCH pathway alterations occurred in 16.7% of tumors. In multivariable Cox regression, NOTCH alterations were an independent favorable prognostic factor (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.24–0.94, p = .03) after adjustment for age, sex, advanced stage, and chemotherapy. DDR alterations did not independently predict survival (HR 1.14, p = .64). Advanced stage independently predicted worse survival (HR 2.38, p < .001), while chemotherapy was associated with better survival (HR 0.44, p = .001). Conclusion: In this SCLC cohort, NOTCH and DDR pathways demonstrate distinct biological roles: NOTCH alterations serve as an independent favorable prognostic marker, while DDR alterations associate with elevated TMB without independent prognostic impact. These findings validate NOTCH as a prognostic biomarker in SCLC and support pathway-level genomic assessment in clinical risk stratification.

Read PDF

Similar papers

Open access Sep 2026

Oncogene-driven genomic profiles are linked to poor overall survival in muscle-invasive bladder cancer (MIBC)

It is suggested that oncogene amplifications, rather than traditional genomic instability metrics, are associated with poor overall survival in MIBC, warranting validation in larger cohorts to assess their potential relevance as prognostic markers and therapeutic targets.

C. Poyet, A. S. Franzen, U. Bieri et al. · 0 citations
Open access Sep 2026

Pathway-integrated genomic analysis of papillary renal cell carcinoma in the WHO 2022 era: cell cycle pathway alterations as an independent adverse prognostic marker-a dual-cohort study

Aims: The 2022 WHO Classification of Renal Tumors introduced molecularly defined entities within papillary renal cell carcinoma (pRCC), removing the historical type 1/type 2 distinction. The independent prognostic significance of these entities and pathway-level alterations in this revised framework remains incompletel...

Elif Sertesen Çamöz, C. Karaçin · 0 citations
Open access Oct 2026

Clinical Utility of Broad-Panel Profiling in Non-Small Cell Lung Cancer: Pairwise Co-Mutational Gene Patterns and PD-L1 Associations Define Stage-Specific Prognosis

Objectives: Precision medicine has improved outcomes in advanced lung cancer, but its implementation remains limited. The prospective LANTERN project (NCT05802771) involves comprehensive clinical and multi-omics data collection. Here, we report preliminary genomic findings, focusing on the prognostic impact of gene mut...

C. Sassorossi, E. De Paolis, Jessica Evangelista et al. · 0 citations
Open access Aug 2026

Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer

The routine implementation of comprehensive genomic profiling in metastatic HER2-negative breast cancer, especially in metastatic HER2-negative breast cancer, is supported to guide precision oncology strategies and enable enrollment in biomarker-driven clinical trials.

E. Papadopoulou, M. Stathoulopoulou, M. Matiatou et al. · 0 citations
Open access Aug 2026

Integrative single-cell and genomic analysis reveals NMB as a driver of metastatic adaptation in esophageal squamous cell carcinoma via metabolic rewiring and immune evasion

NMB serves as a key driver of metastatic adaptation in ESCC, conferring a survival advantage to tumor cells during metastatic colonization through genomic evolution and immune remodeling, with metabolic adaptation as a downstream consequence of genomic alterations.

Zhi-Kai Cao, Dong-Chen Tian, Long He et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.